Chemotherapy-Induced Neutropenia Pipeline Insight 2025: Advancing Beyond G-CSFs Toward Multimodal Protection | DelveInsight

DelveInsight's "Chemotherapy-Induced Neutropenia (CIN) - Pipeline Insight, 2025" delivers an in-depth review of emerging therapies aimed at preventing and managing one of the most common and dose-limiting toxicities of cancer treatment. Chemotherapy-induced neutropenia is characterized by a sharp decline in neutrophils, increasing the risk of infections, hospitalization, and treatment interruptions, ultimately compromising cancer outcomes.

Currently, granulocyte colony-stimulating factors (G-CSFs) like filgrastim and pegfilgrastim dominate the CIN treatment landscape. However, their limitations-such as bone pain, insufficient response in some patients, and inability to fully prevent febrile neutropenia-have catalyzed innovation beyond traditional biologics. The pipeline now includes long-acting G-CSF formulations, receptor agonists, and novel agents aimed at preserving bone marrow function and accelerating neutrophil recovery.

Several investigational therapies are exploring mechanisms like interleukin modulation, toll-like receptor activation, and stem cell niche protection. These next-generation agents aim not only to reduce neutropenia incidence and severity but also to provide protection against multiple hematologic toxicities simultaneously-supporting the shift toward comprehensive supportive care strategies in oncology.

Precision-based risk assessment models, real-world evidence, and digital health tools are also being integrated into trial designs to improve patient selection and optimize treatment timing. Moreover, regulatory incentives such as breakthrough therapy and fast-track designations are accelerating the development of novel CIN therapies, especially in the context of myelosuppressive regimens in aggressive solid tumors and hematologic malignancies.

With a robust pipeline of agents in various stages of development-from early-phase trials to near-market candidates-the Chemotherapy-Induced Neutropenia therapeutic landscape is poised for a paradigm shift, offering safer, more effective, and patient-tailored approaches to neutropenia prevention and management.

Interested in learning more about the current treatment landscape and the key drivers shaping the chemotherapy-induced neutropenia pipeline? Click here: https://www.delveinsight.com/report-store/chemotherapy-induced-neutropenia-cin-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Key Takeaways from the Chemotherapy-Induced Neutropenia Pipeline Report
• DelveInsight's chemotherapy-induced neutropenia pipeline analysis depicts a strong space with 3+ active players working to develop 3+ pipeline drugs for chemotherapy-induced neutropenia treatment.
• The leading chemotherapy-induced neutropenia companies include Aileron, Enzychem Lifesciences, Myelo Therapeutics GmbH, BeyondSpring Inc., and others are evaluating their lead assets to improve the chemotherapy-induced neutropenia treatment landscape.
• Key Chemotherapy-Induced Neutropenia pipeline therapies in various stages of development include ALRN-6924, EC-18, myelo001, Plinabulin, and others.
• Phase III results for 8MW0511, a novel G‐CSF fusion protein delivered once per chemotherapy cycle, were published on May 6, 2025, showing non‐inferiority to PEG‐rhG‐CSF in breast cancer patients receiving TC/TAC chemotherapy.
• A Phase III trial of telpegfilgrastim in non‐small cell lung cancer was published on March 17, 2025, demonstrating non‐inferior efficacy in reducing grade 4 neutropenia compared to rhG‐CSF or PEG‐rhG‐CSF in four chemotherapy cycles.
• The Guard‐02 study of efbemalenograstim alfa released interim data in early 2025, confirming safety and efficacy in prophylactic CIN treatment with a single 20 mg dose.

Request a sample and discover the recent breakthroughs happening in the chemotherapy-induced neutropenia pipeline landscape at https://www.delveinsight.com/report-store/chemotherapy-induced-neutropenia-cin-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Chemotherapy-Induced Neutropenia Overview
Chemotherapy-Induced Neutropenia (CIN) is a common and serious side effect of cancer treatment, characterized by an abnormally low count of neutrophils, a type of white blood cell vital for fighting infections. CIN increases the risk of infections, delays treatment cycles, and can significantly impact patient outcomes and quality of life. Management of CIN often includes the use of granulocyte colony-stimulating factors (G-CSFs) to stimulate neutrophil production, dose adjustments in chemotherapy, and preventive antibiotics in some cases. Research is ongoing to develop more effective and less toxic therapies to manage and prevent CIN, aiming to improve the safety of chemotherapy regimens and reduce hospitalization and infection-related complications.

Find out more about chemotherapy-induced neutropenia medication at https://www.delveinsight.com/report-store/chemotherapy-induced-neutropenia-cin-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Chemotherapy-Induced Neutropenia Treatment Analysis: Drug Profile
ALRN-6924: Aileron
ALRN-6924 is a targeted therapy designed to protect healthy cells in patients with p53-mutated cancers, aiming to reduce chemotherapy-induced side effects without affecting its cancer-killing effect.

EC-18: Enzychem Lifesciences
EC-18 is a synthetic compound originally derived from Sika deer antler, developed for multiple indications, including chemotherapy-induced neutropenia, oral mucositis, and acute radiation syndrome. It is Enzychem's lead candidate, backed by extensive preclinical and clinical research.

Learn more about the novel and emerging chemotherapy-induced neutropenia pipeline therapies at https://www.delveinsight.com/report-store/chemotherapy-induced-neutropenia-cin-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Chemotherapy-Induced Neutropenia Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

By Molecule Type
• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

Scope of the Chemotherapy-Induced Neutropenia Pipeline Report
• Coverage: Global
• Key Chemotherapy-Induced Neutropenia Companies: Aileron, Enzychem Lifesciences, Myelo Therapeutics GmbH, BeyondSpring Inc., and others.
• Key Chemotherapy-Induced Neutropenia Pipeline Therapies: ALRN-6924, EC-18, myelo001, Plinabulin, and others.

To dive deep into rich insights for drugs used for chemotherapy-induced neutropenia treatment, visit: https://www.delveinsight.com/report-store/chemotherapy-induced-neutropenia-cin-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Chemotherapy-Induced Neutropenia Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Chemotherapy-Induced Neutropenia Pipeline Therapeutics
6. Chemotherapy-Induced Neutropenia Pipeline: Late-Stage Products (Phase III)
7. Chemotherapy-Induced Neutropenia Pipeline: Mid-Stage Products (Phase II)
8. Chemotherapy-Induced Neutropenia Pipeline: Early Stage Products (Phase I)
9. Therapeutic Assessment
10. Inactive Products
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

This release was published on openPR.